ArticleFrontiers in medicine2025
Platelet-to-hemoglobin ratio and stroke prognosis in older adults: a nonlinear and inflammation-mediated association.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The platelet-to-hemoglobin ratio (PHR) has been suggested as a prognostic biomarker in several diseases, but its relevance to short-term outcomes in older patients with acute ischemic stroke (AIS) remains uncertain. This study aimed to assess the association between the PHR and 3-month unfavorable outcomes in AIS patients. Methods: We analyzed data from 1,470 older patients with AIS admitted to Seoul National University Hospital between 2010 and 2016. The primary outcome was a 3-month unfavorable outcome, defined as a modified Rankin scale score ≥3. The associations between the PHR and unfavorable outcomes were assessed using multivariable logistic regression. Receiver operating characteristic (ROC) curve analysis and bootstrap mediation analysis were also conducted. Results: A total of 462 older patients (31.43%) experienced unfavorable outcomes. A nonlinear relationship between the PHR and patient prognosis was identified. While no significant association was observed below a threshold of 1.217, the risk of unfavorable outcomes increased significantly beyond this threshold (OR = 1.479; 95% CI: 1.158, 1.888). The area under the ROC curve for the PHR was 0.59 (95% CI, 0.558, 0.622), which was greater than that of the platelet count or hemoglobin alone in predicting unfavorable outcomes. Subgroup analysis revealed that the association was stronger in patients with hyperlipidemia. Bootstrap mediation analysis further revealed that high-sensitivity C-reactive protein (hs-CRP) partially mediated the relationship between PHR and adverse outcomes. Conclusion: A nonlinear association was identified between the PHR and 3-month unfavorable outcomes in older patients with AIS. Subgroup analysis revealed that this association was more significant in patients with hyperlipidemia. Furthermore, mediation analysis indicated that hs-CRP partially mediated this relationship. These findings support the potential utility of the PHR as a practical biomarker for early prognostic stratification in AIS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.